Xiong Wang

IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.

Huji Xu, Ling Zhou, Ting Li, 2019, The Lancet Rheumatology.

Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data

Haixia Zhu, Yu Zhang, Shi-jun Li, 2020, Drug design, development and therapy.

Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab

Wei Li, Jianmin Yang, Yuankai Shi, 2020, EBioMedicine.

IMRT Treatment for Nasopharyngeal Carcinoma (NPC) Is Superior for Relieving Xerostomia, Improving Quality of Life and Protecting the Parotid Glands

Linjun Hu, Zhenzhen Wu, Xiong Wang, 2021 .